1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Graves Orbitopathy: new trials by email Literature Review of Graves Orbitopathy trials Research Report on Graves Orbitopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Secukinumab, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2021-11-29 | 2026-04-15 |
Exophthalmos (1) · Graves Ophthalmopathy (1)
Autoimmune Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine System Diseases (1) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Goiter (1) · Graves Disease (1) · Hyperthyroidism (1) · Immune System Diseases (1) · Orbital Diseases (1) · Thyroid Diseases (1)
secukinumab (1)
Germany (1)